Long-term survival in a randomized study of nonplatinum therapy versus platinum in advanced epithelial ovarian cancer
Autor: | Salvatore Tumolo, Maria Ornella Nicoletto, Roberto Sorio, G. Artioli, O. Nascimben, L. Endrizzi, Martin Donach, O. Vinante, G.P. Cima, G. Cartei |
---|---|
Rok vydání: | 2007 |
Předmět: |
Adult
Oncology medicine.medical_specialty endocrine system diseases First line medicine.medical_treatment chemistry.chemical_element Platinum Compounds Disease-Free Survival law.invention Randomized controlled trial law Internal medicine Antineoplastic Combined Chemotherapy Protocols Long term survival Humans Medicine Epithelial ovarian cancer Stage (cooking) Aged Ovarian Neoplasms Chemotherapy business.industry Carcinoma Obstetrics and Gynecology Middle Aged medicine.disease female genital diseases and pregnancy complications chemistry Female business Ovarian cancer Platinum |
Zdroj: | International Journal of Gynecologic Cancer. 17:986-992 |
ISSN: | 1525-1438 1048-891X |
Popis: | The purpose of this study was to compare long-term survival in first-line chemotherapy with and without platinum in advanced-stage ovarian cancer. From July 1987 to November 1992, 161 untreated patients with FIGO stage III–IV epithelial ovarian cancer were randomized: 81 patients received no platinum and 80 received platinum combination. Residual disease after surgery was P= 0.7960). Stable disease was observed in 18% of patients in nonplatinum arm and 15% of patients in platinum arm and progression in 20% of nonplatinum- and 21% of platinum-treated cases. Ten-year disease-free survival was 37% for therapy without platinum and 31% for platinum combination (P= 0.5679); 10-year overall survival was 23% without platinum and 31% with platinum combination (P= 0.2545). Fifteen-year overall survival showed a trend of short duration in favor of platinum (P= 0.0678). Relapses occurred after 60 months in ten patients (seven with and three without platinum). The overall and disease-free survivals at 5, 10, and 15 years show no statistically significant long-term advantage from the addition of cisplatin; however, there is a slight trend in its favor. |
Databáze: | OpenAIRE |
Externí odkaz: |